SCHEMBL29771997

SCHEMBL29771997

O=C1C=C(c2c[nH]c3ccccc23)C(=O)N1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 7/20 0.65
CDK4 P11802 3/20 0.65
CCND1 P24385 3/20 0.65
CDK2 P24941 3/20 0.65
PRKCA P17252 2/20 0.65
CCNE2 O96020 2/20 0.65
PRKACA P17612 2/20 0.65
PRKACG P22612 2/20 0.65
PRKACB P22694 2/20 0.65
CCNE1 P24864 2/20 0.65
CAMK2D Q13557 2/20 0.65
SIRT2 Q8IXJ6 2/20 0.65
ABL1 P00519 2/20 0.65
PRKD3 O94806 1/20 0.65
CCNB2 O95067 1/20 0.65
PRKCG P05129 1/20 0.65
CDK1 P06493 1/20 0.65
PIM1 P11309 1/20 0.65
CCNB1 P14635 1/20 0.65
PRKCH P24723 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2193383 1.00 PRKCB (0.65) PRKCBCDK4CCND1CDK2PRKCA
Indazole SCHEMBL28147212 0.85 PRKCB (0.49) PRKCBCDK4CCND1CDK2PRKCA
Ro-316233 SCHEMBL624896 0.79 PRKCB (1.00) PRKCBCDK4CCND1CDK2PRKCA
Ro-316233 SCHEMBL29373011 0.79 PRKCB (1.00) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL7951074 0.79 PTPN1 (0.73) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL27866859 0.79 PIK3CD (0.45) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL5879200 0.78 CDK4 (0.46) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL5879319 0.78 CDK4 (0.49) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL5879170 0.78 F7 (0.45) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL5879255 0.78 IGF1R (0.50) PRKCBCDK4CCND1CDK2PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240034799-A1 METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS CEDARS SINAI MEDICAL CENTER (US) 2024-02-01 US disclosed
US-20230279491-A1 TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS CEDARS-SINAI MEDICAL CENTER 2023-09-07 US disclosed
US-11578060-B2 JAK3 selective inhibitor PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) 2023-02-14 US disclosed
CN-110381918-B Cosmetic composition ELC 管理有限责任公司 2022-08-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578060-B2 JAK3 selective inhibitor JAK3, JAK1, JAK2 PRKCB 503/4885CDK4 506/4885CCND1 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.